Healthcare ❯ Pharmaceutical Industry ❯ Drug Development

Clinical Trials

Regulatory Affairs Innovative Therapies Regulatory Approval Phase III Trials Market Launch Prophylactic Treatments Patient Data

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

GSK moves to fortify its immunology pipeline with a mid‑stage anti‑IgE drug that could shift food‑allergy care.

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion